The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease

Self Cite

Nonalcoholic fatty liver disease (NAFLD) is highly related to cardiovascular disorders risk factors. This study aimed to evaluate the effects of black seed (Nigella sativa) supplementation on cardiovascular disorders risk factors in patients with NAFLD. This randomized, double‐blind, placebo‐controlled clinical trial was conducted on 50 patients with NAFLD. Participants were assigned to receive a lifestyle modification plus 2 g/day of either N. sativa or placebo for 12 weeks. Compared with the placebo, N. sativa supplementation led to significant reductions in serum glucose (−7.95 vs. −1.22; p = .041), serum insulin (−3.87 vs. −1.07; p = .027), homeostatic model of assessment for insulin resistance (−1.02 vs. −0.28; p = .021), and a significant increase in quantitative insulin sensitivity check index (0.03 vs. 0.006; p = .002). All of these changes were remained significant after adjusting for known confounding variables; however, there was no significant difference in lipid profile changes between the two groups (p = .05). N. sativa supplementation significantly decreased hepatic steatosis percentage compared with the placebo after adjustment for confounding variables (p = .005). In conclusion, our results indicate that daily intake of 2‐g N. sativa plus lifestyle modification is superior to lifestyle modification alone in amelioration of insulin resistance and hepatic steatosis in patients with NAFLD.

Section: Introductionmentioning

confidence: 99%

The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled clinical trial

Darand

Darabi

Yari

et al. 2019

Self Cite

“…We excluded nine other studies because of the following reasons: (a) Seven articles were derived from the same trials and reported the same outcomes. We included the most complete ones to avoid double weighting in the estimates derived from the same studies (Jazayeri‐Tehrani et al, ; Navekar et al, ; Saadati et al, ). (b) Trials without placebo or control group were excluded ( n = 2; Panahi, Kianpour, Mohtashami, Soflaei, & Sahebkar, ).…”

Section: Resultsmentioning

confidence: 99%

“…In the overall pooled estimate of eight trials (Chashmniam et al, ; Cicero et al, ; Jazayeri‐Tehrani et al, ; Mirhafez et al, ; Navekar et al, ; Panahi et al, ; Rahmani et al, ; Saadati et al, ) with 520 participants (a dose ranging from 70 to 3,000 mg/day), it was shown that curcumin supplementation was associated with a significant reduction in BMI (WMD = −0.34 kg/m 2 , 95% CI [−0.64, −0.04], p < .05) compared with the control group (Figure ). The heterogeneity among trials investigating the effect of curcumin supplementation on BMI was high ( I 2 = 63.2%, p < .01).…”

Section: Resultsmentioning

confidence: 99%

“…Sex studies including a total of 353 participants (curcumin group = 181 and control group = 172) reported body weight as an outcome measure (Chashmniam et al, ; Jazayeri‐Tehrani et al, ; Mirhafez et al, ; Navekar et al, ; Rahmani et al, ; Saadati et al, ). Combined results from the random‐effects model showed that curcumin supplementation had no significant effect on body weight (WMD = −0.60 kg, 95% CI [−2.07, 0.87], p = .423) with significant heterogeneity among the studies ( I 2 = 81.8%, p < .001; Figure ).…”

Section: Resultsmentioning

confidence: 99%

“…The results from meta‐analysis of four trials (Cicero et al, ; Jazayeri‐Tehrani et al, ; Panahi et al, ; Saadati et al, ) with 301 participants (curcumin group = 153 and control group = 148) showed that daily supplementation of curcumin had a significant reducing effect on WC (WMD = −2.12 cm, 95% CI [−3.26, −0.98], p < .001) as compared with placebo using random‐effect model (Figure ). Nonlinear dose–response meta‐analysis showed a significant effect of supplementation dosage on WC ( p nonlinearity = .005, goodness of fit = 4.13; Figure ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose–response meta‐analysis of randomized controlled trials

Baziar

Parohan

2019

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver‐related morbidity; its prevalence is elevating due to the rising epidemic of obesity. Several clinical trials have examined the effects of curcumin supplementation on anthropometric variables in NAFLD patients with inconclusive results. This dose–response meta‐analysis aimed to evaluate the impact of curcumin supplementation on body mass index (BMI), body weight, and waist circumference (WC) in patients with NAFLD. A systematic review of the literature was conducted using PubMed/Medline, ISI Web of Science, Scopus, Cochrane Library, EMBASE, Google Scholar, Sid.ir, and http://Magiran.com to identify eligible studies up to March 2019. A meta‐analysis of eligible studies was performed using the random‐effects model to estimate the pooled effect size. Eight randomized controlled trials with 520 participants (curcumin group = 265 and placebo group = 255) were included. Supplementation dose and duration ranged from 70 to 3,000 mg/day and 8 to 12 weeks, respectively. Curcumin supplementation significantly reduced BMI (weighted mean difference [WMD] = −0.34 kg/m2, 95% CI [−0.64, −0.04], p < .05) and WC (WMD = −2.12 cm, 95% CI [−3.26, −0.98], p < .001). However, no significant effects of curcumin supplementation on body weight were found. These results suggest that curcumin supplementation might have a positive effect on visceral fat and abdominal obesity that have been associated with NAFLD.

Impact of curcumin on fatty acid metabolism

Nosrati‐Oskouie

Aghili-Moghaddam

Sathyapalan

et al. 2021

Free fatty acids (FFAs) and fatty acid synthesis (FAS) activity have significantly contributed to disease states such as insulin resistance, obesity, type 2 diabetes, myocardial infarction, blood pressure, and several types of cancer. Currently, several treatment options are available for patients with these conditions. Due to safety concerns, adverse effects, limited efficacy, and low tolerability associated with many medications, the identification of novel agents with less toxicity and a more favorable outcome is warranted. Curcumin is a phenolic compound derived from the turmeric plant with various biological activities, including anticarcinogenic, antioxidant, antiinflammatory, and hypolipidemic properties. PubMed, Scopus, and Web of Science were searched up to February 2020 for studies that demonstrated the efficacy and mechanisms of curcumin action on FFAs, FAS, and β‐oxidation activity, as well as the desaturation system. Most of the evidence is in‐vivo and in‐vitro studies that demonstrate that curcumin possesses regulatory properties on FFAs levels through its effects on FAS and β‐oxidation activity as well as desaturation system, which could improve insulin resistance, obesity, and other FFAs‐related disorders. The present study provides a review of the existing in‐vitro, in‐vivo, and clinical evidence on the effect of curcumin on FFAs and FAS activity, β‐oxidation, and desaturation system.